Beyond Biosimilars: ADCs, Multi-specific Antibodies, and AI
"We Will Advance Global Partnering to the Next Level"

Celltrion achieved its largest-ever business results at the world’s largest bio industry event, accelerating its transition beyond biosimilars to become a leader in the development of ADCs (antibody-drug conjugates), multi-specific antibodies, and AI-driven new drugs.


Celltrion BioUSA Booth. Celltrion

Celltrion BioUSA Booth. Celltrion

View original image

Celltrion announced on the 26th that it participated in the “2026 BIO International Convention (BIO USA)” held in San Diego, United States, from June 22 to 25 (local time), conducting more than 180 business meetings with global pharmaceutical and biotech companies. This marks the highest number of meetings since Celltrion first began attending BIO USA. BIO USA is the world’s largest bio industry event, attracting over 1,500 pharmaceutical and biotech companies, investors, and research institutions from around the globe, with more than 20,000 industry professionals in attendance. Since 2010, Celltrion has participated in this event for 17 consecutive years, expanding its global network and showcasing its technological competitiveness.


At this year’s convention, Celltrion’s teams specializing in ADC and multi-specific antibody drug development—key drivers of the company’s future growth—were present to actively seek opportunities for joint development and technological collaboration. In addition, the company showcased its AI-powered capabilities, including new target discovery and portfolio expansion, next-generation multi-specific antibody design technologies, feasibility evaluation techniques, and data-driven research platforms. In the materials, parts, and equipment sector, Celltrion discussed ways to enhance production efficiency and strengthen technology through collaboration with multiple global companies, with related discussions set to continue after the event.


This year, more than 2,000 visitors attended the Celltrion booth over four days, marking a record high for both the number of meetings and visitors. Celltrion operated exhibition content that introduced its AI-based new drug development strategy and vision for future growth, and engaged visitors with a giveaway event for customizable keycaps for survey participants, generating enthusiastic responses.



A Celltrion representative stated, “Interest in next-generation growth drivers, such as new drug development in ADCs and multi-specific antibodies and AI-based technologies, was higher than ever before, extending beyond our established biosimilar business. We will further advance the global partnering opportunities identified at this event and do our utmost to ensure that next-generation growth drivers lead to tangible results.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing